n	Hospitalization for Adverse Events	Number of People per Year	Incidence of Rehospitalization				P Value
					(/1000 People/Yr)				(Chi-Square Test)
					Incidence	95% Confidence Intervala
Total	Pimobendan prescription group	251	3	468.31	6.41	1.45	-	11.37	0.315
	Non-prescription group	251	1	415.74	2.41	-0.63	-	5.45
Torsade de pointes	Pimobendan prescription group	251	0	467.93	0	0	-	0	-
	Non-prescription group	251	0	415.74	0	0	-	0
Transient ventricular fibrillation	Pimobendan prescription group	251	0	467.93	0	0	-	0	-
	Non-prescription group	251	0	415.74	0	0	-	0
Ventricular fibrillation	Pimobendan prescription group	251	1	467.93	2.14	-0.73	-	5	0.317
	Non-prescription group	251	0	415.74	0	0	-	0
Ventricular tachycardia	Pimobendan prescription group	251	1	467.93	2.14	-0.73	-	5	1
	Non-prescription group	251	1	415.74	2.41	-0.63	-	5.45
Nonsustained ventricular tachycardia	Pimobendan prescription group	251	1	468.31	2.14	-0.73	-	5	0.317
	Non-prescription group	251	0	415.74	0	0	-	0
Pulseless ventricular tachycardia	Pimobendan prescription group	251	0	467.93	0	0	-	0	-
	Non-prescription group	251	0	415.74	0	0	-	0